PDCD1 and neoplasm: In a Cox proportional hazards model for progression adjusted for age, sex, ethnicity, tumor type, PD-1 inhibitor use, prior radiation therapy, number of prior chemotherapies, concurrent ipilimumab therapy and occurrence of immune-related adverse events, there were a number of associations with lymphopenia and progression as shown in Table 3.